Developer docs
API playgroundTry for free, no card

Search company profiles

Oncopeptides

Full company profile

uuid0003rqd

Namestring
Oncopeptides
Legal namestring
Oncopeptides AB (publ)
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Oncopeptides AB (publ) is a Swedish clinical-stage biotech, founded in 2000 and listed on Nasdaq Stockholm (ticker: ONCO), that develops and commercializes targeted therapies for difficult-to-treat cancers. Its core product, Pepaxti (melflufen/melphalan flufenamide), is the first Peptide Drug Conjugate (PDC) with an alkylating payload, designed to release a cytotoxic alkylator inside multiple myeloma cells via peptidases and esterases overexpressed in tumor tissue. Pepaxti is approved in the EU/EEA/UK (and conditionally in the US under the Pepaxto brand) for adult patients with relapsed/refractory multiple myeloma who have received at least three prior lines of therapy. The company also operates the SPiKE innovation platform for additional candidates and is advancing its PDC platform into glioblastoma based on its blood-brain barrier penetration capability.

The company makes money primarily through direct Pepaxti product sales to hospitals and specialty pharmacies in four owned European markets — Germany (including Austria, its largest market), Italy, Spain, and indirectly through Norway, the UK, and Iceland — supplemented by revenue-sharing distribution partnerships covering Central and Eastern Europe via Salus (11 countries), Greece, South Korea, the Middle East, and Africa. Pricing is reimbursement-driven and varies by country. Go-to-market combines enterprise field sales targeting hematologists and oncologists at major treatment centers with event-driven engagement at major hematology congresses (EHA, COMy, EMN) and KOL-driven real-world evidence generation. Capital structure is supported by a SEK 200M rights issue completed in March 2026 and a conditional EUR 30M European Investment Bank facility, with positive cash flow targeted for 2027.

Short descriptiontext

Oncopeptides is a Swedish biotech that develops and commercializes Pepaxti (melflufen), a first-in-class Peptide Drug Conjugate for relapsed/refractory multiple myeloma, with a pipeline expanding into glioblastoma via its proprietary PDC and SPiKE platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multiple myeloma therapy, peptide drug conjugates, oncology pharmaceuticals, targeted cancer therapy, hematology treatments
Industry3 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Pharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pepaxti Product Sales
TypeOne Time License
Description

Direct commercialization of Pepaxti (melflufen) in European markets through owned commercial infrastructure. Revenue generated from product sales to hospitals and specialty pharmacies in Germany, Austria, Italy, and Spain. Q4 2025 net sales of SEK 18.6 million (88% YoY increase), full-year 2025 net sales more than doubled to SEK 71.1 million.

seekingalpha.com
2Distribution Partnerships
TypeTransaction Fee
Description

Revenue sharing arrangements with regional distribution partners. Salus handles commercialization in Central and Eastern Europe (Slovenia, Croatia, Hungary, Slovakia, Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, Estonia) with revenue shared between Oncopeptides and Salus, with Oncopeptides retaining the larger portion. Similar arrangements for South Korea, Middle East, and Africa.

oncopeptides.com
3European Investment Bank Loan
TypeLicensing Royalties
Description

Unsecured loan agreement with European Investment Bank providing access to conditional loan of up to €30 million structured in three tranches with five-year maturity, contingent on meeting specific milestones related to Pepaxti and Pepaxto cancer therapies.

theglobeandmail.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Pepaxti
Description

Flagship drug (melflufen) - first Peptide Drug Conjugate with an alkylating payload for treatment of multiple myeloma

oncopeptides.com
+4 more records
Core offering1 text field

Oncopeptides develops and commercializes Pepaxti (melflufen), the first Peptide Drug Conjugate (PDC) with an alkylating payload approved in Europe for the treatment of adult patients with relapsed, refractory multiple myeloma who have received at least three prior lines of therapy. The drug leverages peptidases and esterases overexpressed in multiple myeloma cells to release a toxic payload inside cancer cells, damaging DNA and killing the cancer cells. The company is expanding the PDC and SPiKE platforms into additional indications, including glioblastoma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • ORR of 41% in heavily pretreated RRMM patients including those refractory to new immunotherapies
+4 more records
Product overview1 text field

Oncopeptides is a Swedish biotech company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company's core product is Pepaxti® (melflufen), a Peptide Drug Conjugate (PDC) that rapidly and selectively delivers cytotoxic agents into cancer cells. The company operates two proprietary technology platforms: the PDC platform for peptide-drug conjugates and the SPiKE platform for additional drug candidates. Pepaxti is currently commercialized in Europe for relapsed, refractory multiple myeloma patients. The pipeline is expanding into new indications including glioblastoma, with PDC-based candidates like OPD5 in development.

Product and service2 records
1Pepaxti (Melflufen)
CategoryOncology Pharmaceutical
Description

Pepaxti (melflufen) is the first Peptide Drug Conjugate (PDC) with an alkylating payload. It is indicated in combination with dexamethasone for adult patients with relapsed, refractory multiple myeloma who have received at least three prior lines of therapy. The drug uses peptidases and esterases overexpressed in multiple myeloma cells to release a toxic payload inside cancer cells, damaging DNA and killing the cancer cells.

2Pepaxto (Melflufen, US brand)
CategoryOncology Pharmaceutical
Description

US brand name for melflufen. Received accelerated approval in September 2021 from FDA for adult patients with relapsed or refractory multiple myeloma. Not currently marketed in the US; product remains registered.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Salus Group
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-26
Description

Oncopeptides signed an agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe. Salus receives exclusive rights to market and sell Pepaxti in 11 countries: Slovenia, Croatia, Hungary, Slovakia, Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, and Estonia. Salus handles local regulatory processes, market access, and commercialization. Revenue is shared between Oncopeptides and Salus, with Oncopeptides retaining the larger portion. The partnership addresses a market potential of approximately 150 million SEK.

oncopeptides.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on the MARINA study, an investigator-initiated, prospective non-interventional study evaluating the real-world effectiveness, safety, and treatment patterns of Pepaxti in Germany. iOMEDICO acts as formal sponsor and coordinator, with Oncopeptides providing financial support. The study observes 50 patients across approximately 25 sites using the SYNERGY platform.

3Academic Institutions (NK Cell Engager Research)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative research with top universities on NK cell engager therapies for multiple myeloma. Study to be presented at ASH 2025. Research demonstrates synergistic anti-myeloma activity and potential advantages over current T-cell-based strategies.

pharmiweb.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for Window-of-Opportunity glioblastoma study (WoO/OP-701 INSULA). Dr. Petter Brandal serves as primary investigator. Study evaluating PDC platform's ability to cross blood-brain barrier.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Amgen developed Tecvayli (teclistamab), a BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma. Direct competitor targeting the same triple-class refractory patient population as Pepaxti, with rapid adoption potentially competing for the same prescribing physicians.

TypeEmerging player
Description

Arcellx is developing CAR-T cell therapies for multiple myeloma, partnered with Gilead/Kite. Represents the next-generation modality competing for the late-line myeloma patient population, with potentially curative intent that could displace Pepaxti's bridging position.

TypeDirect peer
Description

Karyopharm markets Xpovio (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved for multiple myeloma. Closest comparable in size, indication focus, and commercialization stage to Oncopeptides - both target relapsed/refractory MM with novel mechanisms and have European commercial efforts.

TypeEmerging player
Description

Bicycle Therapeutics develops Bicycle Toxin Conjugates (BTCs) - a structurally analogous technology platform to Oncopeptides' PDC platform, with a focus on oncology including multiple myeloma. Most direct technology peer with similar mechanism of action (targeted cytotoxic delivery) and platform-extension approach.

TypeDirect peer
Description

Johnson & Johnson's Janssen division markets Darzalex (daratumumab) - the market-leading CD38 monoclonal antibody for multiple myeloma - plus Carvykti CAR-T therapy with Legend Biotech. The dominant commercial force in multiple myeloma globally and the standard-setter against which Pepaxti's late-line positioning is judged.

TypeEmerging player
Description

Legend Biotech co-developed Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy with Johnson & Johnson. Direct competitor in the late-line multiple myeloma space whose expanding adoption could constrain the addressable market for Pepaxti over time.

TypeBroad incumbent
Description

AstraZeneca has built a major oncology franchise including through the Alexion acquisition covering hematology, with multiple programs in hematological malignancies. Broad incumbent with deep commercial capability across European markets and active investment in next-generation oncology platforms.

TypeDirect peer
Description

GSK developed Blenrep (belantamab mafodotin), an antibody-drug conjugate targeting BCMA for multiple myeloma. Direct competitor in BCMA-directed therapy and ADCs - a competitive modality that has had regulatory ups and downs creating market dynamics relevant to Pepaxti's positioning.

TypeDirect peer
Description

Takeda markets Ninlaro (ixazomib) and has a substantial multiple myeloma franchise through the Millennium legacy. Competes in the same hematology/oncology specialty channel in Europe and globally, with deep relationships among the same hematologist/oncologist prescriber base.

10Bristol Myers Squibb
TypeDirect peer
Description

Bristol Myers Squibb is a leading multiple myeloma drug developer with Empliciti (elotuzumab) and Revlimid (lenalidomide), and through Celgene acquisition holds Pomalyst. Direct competitor in the multiple myeloma space with established commercial infrastructure across all major geographies where Oncopeptides competes or aims to compete.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncopeptides

Oncology Pharmaceuticalsoncopeptides.com

Oncopeptides is a Swedish biotech that develops and commercializes Pepaxti (melflufen), a first-in-class Peptide Drug Conjugate for relapsed/refractory multiple myeloma, with a pipeline expanding into glioblastoma via its proprietary PDC and SPiKE platforms.

What Oncopeptides does

Oncopeptides AB (publ) is a Swedish clinical-stage biotech, founded in 2000 and listed on Nasdaq Stockholm (ticker: ONCO), that develops and commercializes targeted therapies for difficult-to-treat cancers. Its core product, Pepaxti (melflufen/melphalan flufenamide), is the first Peptide Drug Conjugate (PDC) with an alkylating payload, designed to release a cytotoxic alkylator inside multiple myeloma cells via peptidases and esterases overexpressed in tumor tissue. Pepaxti is approved in the EU/EEA/UK (and conditionally in the US under the Pepaxto brand) for adult patients with relapsed/refractory multiple myeloma who have received at least three prior lines of therapy. The company also operates the SPiKE innovation platform for additional candidates and is advancing its PDC platform into glioblastoma based on its blood-brain barrier penetration capability.

The company makes money primarily through direct Pepaxti product sales to hospitals and specialty pharmacies in four owned European markets — Germany (including Austria, its largest market), Italy, Spain, and indirectly through Norway, the UK, and Iceland — supplemented by revenue-sharing distribution partnerships covering Central and Eastern Europe via Salus (11 countries), Greece, South Korea, the Middle East, and Africa. Pricing is reimbursement-driven and varies by country. Go-to-market combines enterprise field sales targeting hematologists and oncologists at major treatment centers with event-driven engagement at major hematology congresses (EHA, COMy, EMN) and KOL-driven real-world evidence generation. Capital structure is supported by a SEK 200M rights issue completed in March 2026 and a conditional EUR 30M European Investment Bank facility, with positive cash flow targeted for 2027.

Oncopeptides firmographics

Firmographics
Name
Oncopeptides
Legal name
Oncopeptides AB (publ)
Website
https://oncopeptides.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Oncopeptides is a Swedish biotech that develops and commercializes Pepaxti (melflufen), a first-in-class Peptide Drug Conjugate for relapsed/refractory multiple myeloma, with a pipeline expanding into glioblastoma via its proprietary PDC and SPiKE platforms.
Ownership category
akta.pro rank

Oncopeptides industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Multiple myeloma therapy
  • Peptide drug conjugates
  • Oncology pharmaceuticals
  • Targeted cancer therapy
  • Hematology treatments

Where Oncopeptides is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices5 records

Markets served

Oncopeptides business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Pepaxti Product Sales: Direct commercialization of Pepaxti (melflufen) in European markets through owned commercial infrastructure. Revenue generated from product sales to hospitals and specialty pharmacies in Germany, Austria, Italy, and Spain. Q4 2025 net sales of SEK 18.6 million (88% YoY increase), full-year 2025 net sales more than doubled to SEK 71.1 million.
  2. Distribution Partnerships: Revenue sharing arrangements with regional distribution partners. Salus handles commercialization in Central and Eastern Europe (Slovenia, Croatia, Hungary, Slovakia, Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, Estonia) with revenue shared between Oncopeptides and Salus, with Oncopeptides retaining the larger portion. Similar arrangements for South Korea, Middle East, and Africa.
  3. European Investment Bank Loan: Unsecured loan agreement with European Investment Bank providing access to conditional loan of up to €30 million structured in three tranches with five-year maturity, contingent on meeting specific milestones related to Pepaxti and Pepaxto cancer therapies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Oncopeptides product offering

Product offering

Core offering

Oncopeptides develops and commercializes Pepaxti (melflufen), the first Peptide Drug Conjugate (PDC) with an alkylating payload approved in Europe for the treatment of adult patients with relapsed, refractory multiple myeloma who have received at least three prior lines of therapy. The drug leverages peptidases and esterases overexpressed in multiple myeloma cells to release a toxic payload inside cancer cells, damaging DNA and killing the cancer cells. The company is expanding the PDC and SPiKE platforms into additional indications, including glioblastoma.

Product overview

Oncopeptides is a Swedish biotech company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company's core product is Pepaxti® (melflufen), a Peptide Drug Conjugate (PDC) that rapidly and selectively delivers cytotoxic agents into cancer cells. The company operates two proprietary technology platforms: the PDC platform for peptide-drug conjugates and the SPiKE platform for additional drug candidates. Pepaxti is currently commercialized in Europe for relapsed, refractory multiple myeloma patients. The pipeline is expanding into new indications including glioblastoma, with PDC-based candidates like OPD5 in development.

Differentiator

Problem solved

Functional benefit

Brands

  • Pepaxti: Flagship drug (melflufen) - first Peptide Drug Conjugate with an alkylating payload for treatment of multiple myeloma
  • Pepaxto
  • PDC Platform
  • SPiKE Platform
  • Oncopeptalks

Products and services

  • Pepaxti (Melflufen) Pepaxti (melflufen) is the first Peptide Drug Conjugate (PDC) with an alkylating payload. It is indicated in combination with dexamethasone for adult patients with relapsed, refractory multiple myeloma who have received at least three prior lines of therapy. The drug uses peptidases and esterases overexpressed in multiple myeloma cells to release a toxic payload inside cancer cells, damaging DNA and killing the cancer cells.
  • Pepaxto (Melflufen, US brand) US brand name for melflufen. Received accelerated approval in September 2021 from FDA for adult patients with relapsed or refractory multiple myeloma. Not currently marketed in the US; product remains registered.

Quantifiable outcome

  • ORR of 41% in heavily pretreated RRMM patients including those refractory to new immunotherapies
  • +4 more outcomes

Companies that use Oncopeptides

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Oncopeptides technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Oncopeptides partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Salus GroupcoreChannel Partner/ Reseller/ Distributor · 26 May 2026Oncopeptides signed an agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe. Salus receives exclusive rights to market and sell Pepaxti in 11 countries: Slovenia, Croatia, Hungary, Slovakia, Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, and Estonia. Salus handles local regulatory processes, market access, and commercialization. Revenue is shared between Oncopeptides and Salus, with Oncopeptides retaining the larger portion. The partnership addresses a market potential of approximately 150 million SEK.
  • iOMEDICOcoreStrategic or Co-development PartnerCollaboration on the MARINA study, an investigator-initiated, prospective non-interventional study evaluating the real-world effectiveness, safety, and treatment patterns of Pepaxti in Germany. iOMEDICO acts as formal sponsor and coordinator, with Oncopeptides providing financial support. The study observes 50 patients across approximately 25 sites using the SYNERGY platform.
  • Academic Institutions (NK Cell Engager Research)minorStrategic or Co-development PartnerCollaborative research with top universities on NK cell engager therapies for multiple myeloma. Study to be presented at ASH 2025. Research demonstrates synergistic anti-myeloma activity and potential advantages over current T-cell-based strategies.
  • Oslo University HospitalminorStrategic or Co-development PartnerPartner for Window-of-Opportunity glioblastoma study (WoO/OP-701 INSULA). Dr. Petter Brandal serves as primary investigator. Study evaluating PDC platform's ability to cross blood-brain barrier.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Oncopeptides competitors and assessment

Company assessment

Direct peers

  • Amgen: Amgen developed Tecvayli (teclistamab), a BCMA-targeting bispecific antibody for relapsed/refractory multiple myeloma. Direct competitor targeting the same triple-class refractory patient population as Pepaxti, with rapid adoption potentially competing for the same prescribing physicians.
  • Karyopharm Therapeutics: Karyopharm markets Xpovio (selinexor), an oral selective inhibitor of nuclear export (SINE) compound approved for multiple myeloma. Closest comparable in size, indication focus, and commercialization stage to Oncopeptides - both target relapsed/refractory MM with novel mechanisms and have European commercial efforts.
  • Johnson & Johnson: Johnson & Johnson's Janssen division markets Darzalex (daratumumab) - the market-leading CD38 monoclonal antibody for multiple myeloma - plus Carvykti CAR-T therapy with Legend Biotech. The dominant commercial force in multiple myeloma globally and the standard-setter against which Pepaxti's late-line positioning is judged.
  • GSK: GSK developed Blenrep (belantamab mafodotin), an antibody-drug conjugate targeting BCMA for multiple myeloma. Direct competitor in BCMA-directed therapy and ADCs - a competitive modality that has had regulatory ups and downs creating market dynamics relevant to Pepaxti's positioning.
  • Takeda Pharmaceutical: Takeda markets Ninlaro (ixazomib) and has a substantial multiple myeloma franchise through the Millennium legacy. Competes in the same hematology/oncology specialty channel in Europe and globally, with deep relationships among the same hematologist/oncologist prescriber base.
  • Bristol Myers Squibb: Bristol Myers Squibb is a leading multiple myeloma drug developer with Empliciti (elotuzumab) and Revlimid (lenalidomide), and through Celgene acquisition holds Pomalyst. Direct competitor in the multiple myeloma space with established commercial infrastructure across all major geographies where Oncopeptides competes or aims to compete.

Emerging players

  • Arcellx: Arcellx is developing CAR-T cell therapies for multiple myeloma, partnered with Gilead/Kite. Represents the next-generation modality competing for the late-line myeloma patient population, with potentially curative intent that could displace Pepaxti's bridging position.
  • Bicycle Therapeutics: Bicycle Therapeutics develops Bicycle Toxin Conjugates (BTCs) - a structurally analogous technology platform to Oncopeptides' PDC platform, with a focus on oncology including multiple myeloma. Most direct technology peer with similar mechanism of action (targeted cytotoxic delivery) and platform-extension approach.
  • Legend Biotech: Legend Biotech co-developed Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy with Johnson & Johnson. Direct competitor in the late-line multiple myeloma space whose expanding adoption could constrain the addressable market for Pepaxti over time.

Broad incumbents

  • AstraZeneca: AstraZeneca has built a major oncology franchise including through the Alexion acquisition covering hematology, with multiple programs in hematological malignancies. Broad incumbent with deep commercial capability across European markets and active investment in next-generation oncology platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Oncopeptides financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncopeptides leadership team

Management profile

Number of profiles

Profiles10 records

Oncopeptides funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncopeptides M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncopeptides

What does Oncopeptides do?

Oncopeptides develops and commercializes Pepaxti (melflufen), the first Peptide Drug Conjugate (PDC) with an alkylating payload approved in Europe for the treatment of adult patients with relapsed, refractory multiple myeloma who have received at least three prior lines of therapy. The drug leverages peptidases and esterases overexpressed in multiple myeloma cells to release a toxic payload inside cancer cells, damaging DNA and killing the cancer cells. The company is expanding the PDC and SPiKE platforms into additional indications, including glioblastoma.

Is Oncopeptides a public or private company?

Oncopeptides is a public company. It is classified as public and is currently operating.

When was Oncopeptides founded?

Oncopeptides was founded in 2000. It employs 51 to 100 people.

Where is Oncopeptides based?

Oncopeptides is headquartered in Stockholm, Sweden, in the Europe region.

How does Oncopeptides make money?

Three revenue lines are on record. Pepaxti Product Sales are the primary driver. The others are distribution Partnerships and european Investment Bank Loan.

Who are Oncopeptides's main competitors?

Direct peers on record are Amgen, Karyopharm Therapeutics, Johnson & Johnson, GSK, Takeda Pharmaceutical and Bristol Myers Squibb. Emerging players are Arcellx, Bicycle Therapeutics and Legend Biotech. AstraZeneca is listed as a broad incumbent.

Does Oncopeptides have an API?

No public API is recorded for Oncopeptides.

What industry is Oncopeptides in?

Oncopeptides's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
News-MedicalNew European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026Oncopeptides AB announced two ASH 2026 abstracts on Pepaxti (melflufen) in relapsed/refractory multiple myeloma, presenting real-world data from Spain and Italy. The studies included 82 heavily pretreated patients, with overall response rates of 32.5% and 48% and manageable safety profiles. The data support Pepaxti's use post-immunotherapy and between immunotherapies.YahooOncopeptides AB (STU:OND) (Q3 2026) Earnings Call Highlights: Record Sales, Third-Line ...Oncopeptides reported Q3 2026 net sales of SEK 28.5 million, up 41% year-over-year, with trailing twelve-month sales exceeding SEK 100 million for the first time. The company received a positive CHMP opinion for a third-line label expansion, which could double the addressable patient population. CEO Sofia Hagis expects Q4 sales to follow a 2024-like trend, with a German launch planned within a month of the European Commission decision.TradingViewONCO: Sales rose 41% YoY as third-line expansion and glioblastoma advancedOncopeptides AB reported Q3 2026 sales up 41% year-over-year, with gross margin near 98% and positive cash flow targeted for 2027. A positive CHMP opinion advanced potential third-line use, while early INSULA findings supported glioblastoma development.TradingViewONCO: Sales grew 41% as third-line expansion and glioblastoma data advanced key growth catalystsOncopeptides AB reported Q3 sales of SEK 28.5 million, up 41% year-over-year, with gross margin at 98%. The company cited third-line Pepaxti expansion and glioblastoma proof-of-concept as key growth catalysts, targeting positive commercial cash flow in 2027.Dagens industriOncopeptides minskade förlustenOncopeptides reported an operating loss of 36.5 million Swedish kronor for the third quarter of 2026, down from 47.1 million kronor in the prior period. CEO Sofia Heigis is named in the report.MarketScreenerOncopeptides to present new Pepaxti data at ASH 2026Oncopeptides will present new Pepaxti data at ASH 2026, including results from 82 patients in Spain and Italy. The Spanish study of 40 patients showed a 32.5% response rate, median progression-free survival of 3.2 months, and overall survival of 15.7 months. The company says the results support Pepaxti's efficacy and manageable safety profile, including after immunotherapy.The future of tradingOncopeptides to host Q3 results presentationOncopeptides will publish its third-quarter 2026 report on November 5 at 08:00 CET. An English-language webcast presentation with a Q&A session is scheduled for November 5 at 09:00 CET.Dagens industriSå stor blev rabatten i OncopeptidesOncopeptides set the subscription price at 2 kronor per share for a 50 million new shares offering, raising 100 million kronor. The offering was announced at market close on Tuesday and approved.EleconomistaLa empresa de biotecnología Oncopeptides recibe el aval de Europa para adelantar el uso de su fármaco Pepaxti contra el mieloma múltipleThe European Medicines Agency's CHMP issued a favorable opinion to expand Pepaxti's indication to third-line myeloma treatment, a recommendation sent to the European Commission. The change removes the requirement of refractoriness to three drug classes, broadening the patient population. The recommendation is based on the OCEAN phase III trial.PharmaTimesPepaxti study supports use in wider myeloma populationOncopeptides reported phase 2 data from the BRIDGE study on Pepaxti plus dexamethasone in relapsed refractory myeloma patients with moderate to severe renal impairment. A 30 mg starting dose yielded a 70% overall response rate and median progression-free survival of 7.7 months, with no new safety signals. The findings support renal function-based dose adjustments for this patient subgroup.